secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARS Pharmaceuticals, Inc. (SPRY)
CIK:        0001671858
Form:       8-K
Filed at:   2022-12-09T23:59:59+00:00
Accession:  0001193125-22-301873
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ARS Pharmaceuticals appoints Brian Dorsey as COO; salary increased to $410,000
------------------------------------------------------------------------------

- Brian Dorsey appointed COO effective December 6, 2022; previously SVP of Operations and Project Management since 2018.
- Base salary raised from $319,800 to $410,000; eligible for annual discretionary bonus up to 40% of base salary.
- Employment agreement is part-time (~35%); Dorsey may engage in other business activities, subject to non-compete in nasal drug development.
- Severance: 3 months base salary and COBRA premiums if terminated without cause or resigns for good reason after 12-month cliff.
- Dorsey holds 120,000-share option grant under 2018 Equity Incentive Plan, vesting monthly over 3 years.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671858/000119312522301873/0001193125-22-301873-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671858/000119312522301873/d772949d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-301873

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer